Advertisement
Screener

Biohaven Ltd. (BHVN) Proceeds from (Payments for) Other Financing Activities

2.8 / 5 stars · 68/120 Roast Me

Biohaven Ltd. Proceeds from (Payments for) Other Financing Activities

Biohaven Ltd. (BHVN) reported Proceeds from (Payments for) Other Financing Activities of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2026-08-10

  • Biohaven Ltd. proceeds from (payments for) other financing activities for the quarter ending 2026-06-30 was $0.00.
  • Biohaven Ltd. proceeds from (payments for) other financing activities for the quarter ending 2026-03-31 was $0.00.
  • Biohaven Ltd. proceeds from (payments for) other financing activities for the quarter ending 2025-12-31 was -$194.00K.
  • Biohaven Ltd. proceeds from (payments for) other financing activities for the quarter ending 2025-09-30 was $0.00.
  • Biohaven Ltd. proceeds from (payments for) other financing activities for fiscal 2025 was -$194.00K, a 108.59% decline from fiscal 2024.
  • Biohaven Ltd. proceeds from (payments for) other financing activities for fiscal 2024 was $2.26M.
  • Biohaven Ltd. proceeds from (payments for) other financing activities for fiscal 2023 was $0.00.
  • Biohaven Ltd. proceeds from (payments for) other financing activities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
Period endProceeds from (Payments for) Other Financing Activities 3 monthProceeds from (Payments for) Other Financing Activities 3 month as first filedProceeds from (Payments for) Other Financing Activities 6 monthProceeds from (Payments for) Other Financing Activities 6 month as first filedProceeds from (Payments for) Other Financing Activities 9 monthProceeds from (Payments for) Other Financing Activities 12 monthProceeds from (Payments for) Other Financing Activities 12 month as first filed
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$0.00
10-Q · filed 2026-08-10
-$194.00K
derived: sum of 3 quarters · filed 2026-08-10
-$194.00K
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$0.00
10-Q · filed 2026-05-04
-$194.00K
derived: sum of 2 quarters · filed 2026-05-04
-$194.00K
derived: sum of 3 quarters · filed 2026-05-04
-$194.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31-$194.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
-$194.00K
derived: sum of 2 quarters · filed 2026-03-02
-$194.00K
derived: sum of 3 quarters · filed 2026-08-10
-$194.00K
10-K · filed 2026-03-02
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$0.00
derived: sum of 2 quarters · filed 2026-08-10
$0.00
10-Q · filed 2025-11-10
$0.00
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$0.00
10-Q · filed 2026-08-10
$0.00
derived: sum of 3 quarters · filed 2026-08-10
$0.00
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$0.00
10-Q · filed 2026-05-04
$0.00
derived: sum of 2 quarters · filed 2026-05-04
$0.00
derived: sum of 3 quarters · filed 2026-05-04
$1.04M
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$0.00
derived: sum of 2 quarters · filed 2026-03-02
$1.04M
derived: sum of 3 quarters · filed 2026-03-02
$2.26M
10-K · filed 2026-03-02
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$1.04M
derived: sum of 2 quarters · filed 2025-11-10
$2.26M
10-Q · filed 2025-11-10
$401.00K
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30$1.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
$2.26M
10-Q · filed 2025-08-11
$401.00K
derived: sum of 3 quarters · filed 2026-03-02
$2.26M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31$1.22M
10-Q · filed 2025-05-12
-$637.00K
derived: sum of 2 quarters · filed 2026-03-02
$1.22M
derived: sum of 3 quarters · filed 2026-03-02
$1.22M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31-$1.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$0.00
derived: sum of 2 quarters · filed 2026-03-02
$0.00
derived: sum of 3 quarters · filed 2026-03-02
$0.00
10-K · filed 2026-03-02
2023-09-30$1.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$1.86M
derived: sum of 2 quarters · filed 2024-11-12
$1.86M
10-Q · filed 2024-11-12
$1.86M
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
$0.00
10-Q · filed 2024-08-09
$1.13M
10-Q · filed 2023-07-31
$0.00
derived: sum of 3 quarters · filed 2025-03-03
$0.00
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$0.00
10-Q · filed 2024-05-09
$332.00K
10-Q · filed 2023-05-12
$0.00
derived: sum of 2 quarters · filed 2025-03-03
$0.00
derived: sum of 3 quarters · filed 2025-03-03
$0.00
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$0.00
derived: sum of 2 quarters · filed 2025-03-03
$0.00
derived: sum of 3 quarters · filed 2025-03-03
$0.00
10-K · filed 2025-03-03
$451.00K
10-K · filed 2023-03-23
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$0.00
derived: sum of 2 quarters · filed 2023-11-14
$0.00
10-Q · filed 2023-11-14
$0.00
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31
$0.00
10-Q · filed 2023-07-31
$0.00
derived: sum of 3 quarters · filed 2023-07-31
2022-03-31$0.00
10-Q · filed 2023-05-12
$0.00
derived: sum of 2 quarters · filed 2023-05-12
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
$395.00K
10-K · filed 2023-03-23
2021-09-30$395.00K
10-Q · filed 2022-11-09
2020-12-31$0.00
10-K · filed 2023-03-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
UroGen Pharma Ltd. (URGN)$2.015B-18.42
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
Generate Biomedicines, Inc. (GENB)United States$2.052B
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55